Opzelura is under clinical development by Incyte and currently in Phase II for Unspecified Dermatological Disorders.

Incyte's Opzelura cream has become the first medical treatment approved to re-pigment the skin of people with vitiligo in the US, adding to its current use in atopic dermatitis.

This article is sponsored by Incyte. Dr. Nada Elbuluk was compensated for her participation. Receiving a vitiligo diagnosis is a lot to process. After all, the chronic autoimmune condition ...

This article is sponsored by Incyte. Vitiligo is a chronic autoimmune condition that manifests as white patches of ...

Now, all eyes are set on the FDA-approved drug Ruxolitinib, manufactured by Incyte Pharmaceuticals, which is the first drug that can restore pigment in patients with nonsegmental vitiligo.

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

Incyte is dropping a program for patients with myelofibrosis-related anemia after its investigational small molecule failed to improve symptoms in a phase 1/2 trial. The drug, zilurgisertib, is ...

In dermatology, Incyte received FDA approval of Opzelura (ruxolitinib cream) in 2021 based on solid phase 3 data; positive phase 3 data supported approval in vitiligo in 2022 in the US and in 2023 ...